DK3415915T3 - Fremgangsmåde til at forudsige respons til PARP-inhibitorer - Google Patents
Fremgangsmåde til at forudsige respons til PARP-inhibitorer Download PDFInfo
- Publication number
- DK3415915T3 DK3415915T3 DK18175350.0T DK18175350T DK3415915T3 DK 3415915 T3 DK3415915 T3 DK 3415915T3 DK 18175350 T DK18175350 T DK 18175350T DK 3415915 T3 DK3415915 T3 DK 3415915T3
- Authority
- DK
- Denmark
- Prior art keywords
- parp inhibitors
- predicting response
- predicting
- response
- parp
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602460P | 2012-02-23 | 2012-02-23 | |
| US201261604810P | 2012-02-29 | 2012-02-29 | |
| EP13755251.9A EP2817630B1 (en) | 2012-02-23 | 2013-02-22 | Methods for predicting anti-cancer response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3415915T3 true DK3415915T3 (da) | 2024-11-04 |
Family
ID=49083171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18175350.0T DK3415915T3 (da) | 2012-02-23 | 2013-02-22 | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| DK13755251.9T DK2817630T3 (da) | 2012-02-23 | 2013-02-22 | Fremgangsmåder til at forudsige en anti-cancer-reaktion |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13755251.9T DK2817630T3 (da) | 2012-02-23 | 2013-02-22 | Fremgangsmåder til at forudsige en anti-cancer-reaktion |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10190160B2 (da) |
| EP (3) | EP2817630B1 (da) |
| AU (1) | AU2013226400B2 (da) |
| CA (2) | CA3080441C (da) |
| DK (2) | DK3415915T3 (da) |
| ES (2) | ES2687024T3 (da) |
| FI (1) | FI3415915T3 (da) |
| NZ (1) | NZ628813A (da) |
| WO (1) | WO2013130347A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2609216T3 (da) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Fremgangsmåder til at forudsige antikræftreaktion |
| EP3693473B1 (en) | 2011-06-17 | 2025-02-19 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| DK3415915T3 (da) | 2012-02-23 | 2024-11-04 | Childrens Medical Center | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US20180163271A1 (en) * | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| ES2946251T3 (es) * | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
| EP3230472A4 (en) * | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| US12537074B2 (en) | 2016-05-01 | 2026-01-27 | Genome Research Limited | Method of characterising a DNA sample |
| EP3452937B1 (en) | 2016-05-01 | 2025-10-22 | Genome Research Limited | Method of characterising a dna sample |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| WO2022081151A1 (en) * | 2020-10-14 | 2022-04-21 | Imprimed, Inc. | Methods and systems for predicting in-vivo response to drug therapies |
| WO2022235636A1 (en) * | 2021-05-03 | 2022-11-10 | Mersana Therapeutics, Inc. | Combination therapy of carboplatin and napi2b-targeted polymer antibody-drug conjugate for the treatment of ovarian cancer |
| WO2023239343A1 (en) * | 2022-06-06 | 2023-12-14 | Memorial Sloan-Kettering Cancer Center | Methods including geometric network analysis for selecting patients with high grade serous carcinoma of the ovary treated with immune checkpoint blockade therapy |
| WO2024083971A1 (en) | 2022-10-19 | 2024-04-25 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| DE3630497A1 (de) | 1986-09-08 | 1988-03-10 | Behringwerke Ag | Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel |
| FI87572C (fi) | 1987-05-08 | 1993-01-25 | Sankyo Co | Foerfarande foer framstaellning av platinakomplex med terapeutisk effekt |
| US4996337A (en) | 1987-06-23 | 1991-02-26 | American Cyanamid Company | Synthesis of cisplatin analogs |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5434256A (en) | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US4946954A (en) | 1989-01-17 | 1990-08-07 | Georgetown University | Platinum pharmaceutical agents |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| WO1993009782A1 (en) | 1991-11-15 | 1993-05-27 | Smithkline Beecham Corporation | Combination chemotherapy |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| CA2284211A1 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6214821B1 (en) | 1998-03-05 | 2001-04-10 | Washington State University Research Foundation | Methods and composition for the inhibition of cancer cells |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| GB9808145D0 (en) | 1998-04-17 | 1998-06-17 | Zeneca Ltd | Assay |
| WO2000009759A1 (en) | 1998-08-17 | 2000-02-24 | The Burnham Institute | Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| EP1141384A2 (en) | 1999-01-06 | 2001-10-10 | Cornell Research Foundation, Inc. | Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| US7858331B2 (en) | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| MXPA03004832A (es) | 2000-12-01 | 2004-05-04 | Guilford Pharm Inc | Compuestos y sus usos. |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| NZ535044A (en) | 2002-03-01 | 2008-12-24 | Ravgen Inc | Non-invasive method to determine the genetic sequence of foetal DNA from a sample from a pregnant female thereby detecting any alternation in gene sequence as compared with the wild type sequence |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| GB0226595D0 (en) * | 2002-11-15 | 2002-12-24 | Univ Belfast | Cancer therapy determination |
| US20070004621A1 (en) | 2003-02-12 | 2007-01-04 | Viji Shridhar | Bex4 nucleic acids, polypeptides, and method of using |
| US20040170983A1 (en) | 2003-02-27 | 2004-09-02 | Danenberg Kathleen D. | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus |
| WO2004083816A2 (en) | 2003-03-14 | 2004-09-30 | John Wayne Cancer Institute | Loss of heterozygosity of the dna markers in the 12q22-23 region |
| WO2005002508A2 (en) | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| DE04777189T1 (de) | 2003-07-02 | 2011-04-07 | Solux Corporation, San Diego | Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür |
| PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| JP2007502301A (ja) | 2003-08-13 | 2007-02-08 | ユニバーシティー オブ サウス フロリダ | 腫瘍細胞の増殖を阻害するための方法 |
| US20080108057A1 (en) * | 2004-06-22 | 2008-05-08 | Griffith Jeffrey K | Allelic imbalance in the diagnosis and prognosis of cancer |
| US7860840B2 (en) | 2004-10-05 | 2010-12-28 | Microsoft Corporation | Maintaining correct transaction results when transaction management configurations change |
| CA2585025A1 (en) | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and purefluid specimens |
| US7563570B2 (en) * | 2004-10-29 | 2009-07-21 | Pangaea Biotech | Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression |
| US20070070349A1 (en) | 2005-09-23 | 2007-03-29 | Helicos Biosciences Corporation | Optical train and method for TIRF single molecule detection and analysis |
| WO2006098978A1 (en) | 2005-03-09 | 2006-09-21 | Abbott Laboratories | Diagnostics method for identifying candidate patients for the treatment with trastuzumab |
| EP1877576B1 (en) | 2005-04-12 | 2013-01-23 | 454 Life Sciences Corporation | Methods for determining sequence variants using ultra-deep sequencing |
| BRPI0609939A2 (pt) | 2005-04-21 | 2010-05-11 | Alza Corp | método para tratar cáncer de ovário avançado com doxorubicina capturada em lipossomas |
| WO2006128195A2 (en) | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
| JP5193032B2 (ja) | 2005-06-30 | 2013-05-08 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | モノアゾールリガンド白金類似体 |
| WO2007035893A2 (en) | 2005-09-21 | 2007-03-29 | Bioarray Solutions, Ltd. | Use of ivt with single stranded primer promoter selector constructs |
| WO2008112193A1 (en) | 2007-03-12 | 2008-09-18 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
| JP5707132B2 (ja) | 2007-09-07 | 2015-04-22 | フルイダイム コーポレイション | コピー数変動の決定、方法およびシステム |
| JP2011503111A (ja) | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| KR20100102637A (ko) | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료 |
| US20090246789A1 (en) | 2008-03-25 | 2009-10-01 | University Of South Carolina | Gene Mutation Profiling of CSMD1 |
| US20100086922A1 (en) | 2008-05-30 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
| WO2010004273A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| CA2739459A1 (en) | 2008-10-31 | 2010-05-06 | Abbott Laboratories | Genomic classification of colorectal cancer based on patterns of gene copy number alterations |
| US8206910B2 (en) | 2008-12-08 | 2012-06-26 | The Cleveland Clinic Foundation | Targets for use in diagnosis, prognosis and therapy of breast cancer |
| KR100925337B1 (ko) | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| WO2011048495A1 (en) * | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
| WO2011058367A2 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US20130079423A1 (en) | 2010-02-24 | 2013-03-28 | Myriad Genetics, Incorporated | Diagnostic methods involving loss of heterozygosity |
| DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
| WO2012019000A2 (en) | 2010-08-04 | 2012-02-09 | On-Q-ity | Biomarkers for the identification monitoring and treatment of ovarian cancer |
| DK2609216T3 (da) * | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Fremgangsmåder til at forudsige antikræftreaktion |
| KR20140024270A (ko) | 2010-12-30 | 2014-02-28 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| EP3693473B1 (en) | 2011-06-17 | 2025-02-19 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| DK3415915T3 (da) | 2012-02-23 | 2024-11-04 | Childrens Medical Center | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| DK2981624T3 (da) | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US20180163271A1 (en) | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| US9575229B2 (en) | 2014-03-19 | 2017-02-21 | Nike, Inc. | Article having a plurality of optical structures |
-
2013
- 2013-02-22 DK DK18175350.0T patent/DK3415915T3/da active
- 2013-02-22 EP EP13755251.9A patent/EP2817630B1/en active Active
- 2013-02-22 AU AU2013226400A patent/AU2013226400B2/en active Active
- 2013-02-22 ES ES13755251.9T patent/ES2687024T3/es active Active
- 2013-02-22 CA CA3080441A patent/CA3080441C/en active Active
- 2013-02-22 FI FIEP18175350.0T patent/FI3415915T3/fi active
- 2013-02-22 WO PCT/US2013/027295 patent/WO2013130347A1/en not_active Ceased
- 2013-02-22 CA CA2864481A patent/CA2864481C/en active Active
- 2013-02-22 NZ NZ628813A patent/NZ628813A/en not_active IP Right Cessation
- 2013-02-22 DK DK13755251.9T patent/DK2817630T3/da active
- 2013-02-22 EP EP18175350.0A patent/EP3415915B1/en active Active
- 2013-02-22 EP EP24202895.9A patent/EP4462120A3/en active Pending
- 2013-02-22 ES ES18175350T patent/ES2997859T3/es active Active
-
2014
- 2014-08-22 US US14/466,208 patent/US10190160B2/en active Active
-
2018
- 2018-12-28 US US16/235,247 patent/US11299782B2/en active Active
-
2022
- 2022-03-01 US US17/683,656 patent/US20220186311A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2817630A4 (en) | 2015-10-28 |
| ES2997859T3 (en) | 2025-02-18 |
| ES2687024T3 (es) | 2018-10-23 |
| EP4462120A2 (en) | 2024-11-13 |
| EP2817630A1 (en) | 2014-12-31 |
| EP4462120A3 (en) | 2025-01-08 |
| EP3415915A1 (en) | 2018-12-19 |
| CA3080441A1 (en) | 2013-09-06 |
| CA2864481A1 (en) | 2013-09-06 |
| CA3080441C (en) | 2026-01-06 |
| WO2013130347A1 (en) | 2013-09-06 |
| US20220186311A1 (en) | 2022-06-16 |
| US10190160B2 (en) | 2019-01-29 |
| CA2864481C (en) | 2020-07-14 |
| US11299782B2 (en) | 2022-04-12 |
| EP3415915B1 (en) | 2024-10-23 |
| US20190136318A1 (en) | 2019-05-09 |
| FI3415915T3 (fi) | 2024-11-29 |
| AU2013226400B2 (en) | 2018-09-06 |
| DK2817630T3 (da) | 2018-10-08 |
| US20150038340A1 (en) | 2015-02-05 |
| EP2817630B1 (en) | 2018-07-11 |
| NZ628813A (en) | 2015-10-30 |
| AU2013226400A1 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2841428T3 (da) | Dna-pk-inhibitorer | |
| SG11201507739TA (en) | Method for predicting sensitivity to egfr inhibitor | |
| HUE058085T2 (hu) | Glükozilceramid-szintáz inhibitorai | |
| DK3512197T5 (da) | Fremgangsmåde til kortlægning af intraprædikationsmodus | |
| DK2751387T3 (da) | Selvsuspenderende proppanter til hydraulisk frakturering | |
| DK2879615T3 (da) | Fremgangsmåde til at bestemme sandsynlighed for brunst | |
| DK2621339T3 (da) | Avanceret system til kontinuerlig analytmonitorering | |
| DK2855993T3 (da) | Fluidumforbindelsesindretning til et kølesystem | |
| DK2518585T3 (da) | Termosifonanordninger til elektroniske enheder | |
| DK2909340T3 (da) | Diagnostisk metode til forudsigelse af tnf alpha inhibitor respons | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| EP2904115A4 (en) | BIOMARKERS AND METHODS FOR PREDICTING RESPONSE TO INHIBITORS AND USES THEREOF | |
| DK2861753T3 (da) | Evalueringssystem til mikroorganismer | |
| EP2785183A4 (en) | TRIAZOLPYRIDINON PDE10 INHIBITORS | |
| DK2858563T3 (da) | Elektromedicinsk system til bestemmelse af neuromuskulkær lammelse | |
| DK2876447T3 (da) | Fremgangsmåde til detektering af cancer | |
| DK2897546T3 (da) | Indretning til automatiseret capsulotomi | |
| FR2999597B1 (fr) | Procede de desasphaltage selectif de charges lourdes | |
| DK2849760T3 (da) | Fremgangsmåder til oligonukleotid-chelatkompleks | |
| EP2775844A4 (en) | BIOMARKER FOR THE RESPONSE TO NAE INHIBITORS | |
| DK2788353T3 (da) | Bur-aminligander til metallo-radiofarmaceutika | |
| BR112014025875A2 (pt) | Método de medição | |
| DK2863985T3 (da) | Anordning til forbedring af mikrocirkulering | |
| EP2858975A4 (en) | FBXO3 INHIBITORS | |
| EP2542702A4 (en) | METHOD FOR PREDICTING THE CONTINUOUS PATTERN OF HORSES |